Candriam S.C.A. 89bio, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in 89bio, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 848,079 shares of ETNB stock, worth $7.48 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
848,079
Previous 848,079
-0.0%
Holding current value
$7.48 Million
Previous $6.79 Million
7.63%
% of portfolio
0.04%
Previous 0.04%
Shares
8 transactions
Others Institutions Holding ETNB
# of Institutions
159Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$134 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$125 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$70.5 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$65.1 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$61.9 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $410M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...